Alzheimer's Germ Quest, Naples, FL, USA.
J Alzheimers Dis. 2021;81(3):921-932. doi: 10.3233/JAD-210080.
Substantial evidence, composed of drug mechanisms of action, in vivo testing, and epidemiological data, exists to support clinical testing of FDA-approved drugs for repurposing to the treatment of Alzheimer's disease (AD). Licensed compound investigation can often proceed at a faster and more cost-effective manner than un-approved compounds moving through the drug pipeline. As the prevalence of AD increases with life expectancy, the current rise in life expectancy amalgamated with the lack of an effective drug for the treatment of AD unnecessarily burdens our medical system and is an urgent public health concern. The unfounded reluctance to examine repurposing existing drugs for possible AD therapy further impedes the possibility of improving the quality of patient lives with a terminal disease. This review summarizes some evidence which exists to suggest certain already-approved drugs may be considered for the treatment of AD and will perhaps encourage physicians to off-label prescribe these safe therapeutics.
大量证据表明，包括药物作用机制、体内试验和流行病学数据，支持对 FDA 批准的药物进行重新定位以治疗阿尔茨海默病（AD）的临床测试。与通过药物研发渠道的未经批准的化合物相比，许可化合物的研究通常可以更快、更具成本效益的方式进行。随着预期寿命的延长，AD 的患病率也在增加，目前预期寿命的上升与缺乏有效的 AD 治疗药物相结合，不必要地给我们的医疗系统带来负担，是一个紧迫的公共卫生问题。人们没有理由不愿意研究重新利用现有药物治疗 AD 的可能性，这进一步阻碍了提高患有绝症的患者生活质量的可能性。这篇综述总结了一些证据，表明某些已批准的药物可能被考虑用于治疗 AD，并可能鼓励医生开出这些安全的治疗药物。
